Q&A with Timothy Oostdyk, Executive Vice-President and Chief Operating Officer of Lancaster Laboratores - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Timothy Oostdyk, Executive Vice-President and Chief Operating Officer of Lancaster Laboratores

Pharmaceutical Technology
Volume 33, Issue 9, pp. 78



PharmTech:
Do you see a new industry trend emerging?

Oostdyk:
Nearly every segment of our industry is experiencing unprecedented financial pressure. People are being required to do more with less. As the pharmaceutical industry tightens its belt, a few trends are emerging.

First, faced with headcount restrictions and reductions, more pharmaceutical and biopharmaceutical companies are looking to us to meet their business objectives while enabling them to maintain a variable cost structure. This has resulted in significant growth of full-time equivalent (FTE) programs and Professional Scientific Staffing (PSS) programs. FTE programs provide dedicated staff in one of our facilities, and PSS programs provide scientific staff in the client's facility. Both models provide cost-effective solutions to our clients' staffing challenges while minimizing their own fixed headcount.

Second, as companies seek to leverage global capabilities more effectively, they are looking for international service providers who can effectively manage the logistics and communication challenges of operating worldwide. Companies require providers that offer rapid access to real-time data and highly effective project management.

Third, we see significant diversification in the pipeline of much of the industry, as companies merge and acquire products. Companies are therefore looking for laboratory service providers with extensive expertise in synthetic pharmaceuticals and biologics, as well as all types of dosage forms.

PharmTech:
What is the most common demand your clients are currently making of you?

Oostdyk:
Today more than ever, our customers are looking for a highly skilled partner that can fulfill all of their needs, from a relatively simple test to the design and execution of a complex testing program to bring a new biologic to market. We have invested in a comprehensive range of scientific services, expertise, and capacity for both traditional pharmaceutical products and biologics. This extensive range of capabilities in our laboratories, combined with our on-site staffing model, enables us to deliver a strategic solution.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here